Jonathan B. Whitchurch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jonathan B. Whitchurch has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- David M. Heery
University of Nottingham
5 shared publications - Nigel Patrick Mongan
School of Veterinary Medicine and Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham LE12 5RD, UK
4 shared publications - Jenny Liao Persson
Department of Molecular Biology, Umeå University, 901 87 Umeå, Sweden
3 shared publications Bismoy Mazumder
School of Pharmacy, University of Nottingham, United Kingdom
2 shared publications- Veronika Maria Metzler
Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Innsbruck, Innsbruck, Austria
2 shared publications - Alan Brown
Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA
1 shared publication
Latest Publications
- Open Access
PKD1L1 Is Involved in Congenital Chylothorax
Besides visceral heterotaxia, Pkd1l1 null mouse embryos exhibit general edema and perinatal lethality. In humans, congenital chylothorax (CCT) is a frequent cause of fetal hydrops. In 2021, Correa and colleagues reported ultrarare compound heterozygous variants in PKD1L1 exhibiting in two consecutive fetuses with severe hydrops, implicating a direct role of PKD1L1 in fetal hydrops formation. Here, we performed an exome survey and identified ultrarare compound heterozygous variants in PKD1L1 in two of the five case–parent trios with CCT. In one family, the affected carried the ultrarare missense variants c.1543G>A(p.Gly515Arg) and c.3845T>A(p.Val1282Glu). In the other family, the affected carried the ultrarare loss-of-function variant (LoF) c.863delA(p.Asn288Thrfs*3) and the ultrarare missense variant c.6549G>T(p.Gln2183His). Investigation of the variants’ impact on PKD1L1 protein localization suggests the missense variants cause protein dysfunction and the LoF variant causes protein mislocalization. Further analysis of Pkd1l1 mutant mouse embryos revealed about 20% of Pkd1l1−/− embryos display general edema and pleural effusion at 14.5 dpc. Immunofluorescence staining at 14.5 dpc in Pkd1l1−/− embryos displayed both normal and massively altered lymphatic vessel morphologies. Together, our studies suggest the implication of PKD1L1 in congenital lymphatic anomalies, including CCTs.
Open AccessPKD1L1 Is Involved in Congenital Chylothorax
Besides visceral heterotaxia, Pkd1l1 null mouse embryos exhibit general edema and perinatal lethality. In humans, congenital chylothorax (CCT) is a frequent cause of fetal hydrops. In 2021, Correa and colleagues reported ultrarare compound heterozygous variants in PKD1L1 exhibiting in two consecutive fetuses with severe hydrops, implicating a direct role of PKD1L1 in fetal hydrops formation. Here, we performed an exome survey and identified ultrarare compound heterozygous variants in PKD1L1 in two of the five case–parent trios with CCT. In one family, the affected carried the ultrarare missense variants c.1543G>A(p.Gly515Arg) and c.3845T>A(p.Val1282Glu). In the other family, the affected carried the ultrarare loss-of-function variant (LoF) c.863delA(p.Asn288Thrfs*3) and the ultrarare missense variant c.6549G>T(p.Gln2183His). Investigation of the variants’ impact on PKD1L1 protein localization suggests the missense variants cause protein dysfunction and the LoF variant causes protein mislocalization. Further analysis of Pkd1l1 mutant mouse embryos revealed about 20% of Pkd1l1−/− embryos display general edema and pleural effusion at 14.5 dpc. Immunofluorescence staining at 14.5 dpc in Pkd1l1−/− embryos displayed both normal and massively altered lymphatic vessel morphologies. Together, our studies suggest the implication of PKD1L1 in congenital lymphatic anomalies, including CCTs.
- Open Access
- 1 October 2018
- Published by Elsevier in EBioMedicine
- Vol. 36, 401-409
Predicting puberty in partial androgen insensitivity syndrome: Use of clinical and functional androgen receptor indices
- 1 October 2018
- Published by Elsevier in EBioMedicine
- Vol. 36, 401-409
Open AccessPredicting puberty in partial androgen insensitivity syndrome: Use of clinical and functional androgen receptor indices
- Open Access
- 16 March 2017
- Published by Springer Nature in Cell Death & Disease
- Vol. 8 (3) , e2677
Heterodimers of photoreceptor-specific nuclear receptor (PNR/NR2E3) and peroxisome proliferator-activated receptor-γ (PPARγ) are disrupted by retinal disease-associated mutations
Photoreceptor-specific nuclear receptor (PNR/NR2E3) and Tailless homolog (TLX/NR2E1) are human orthologs of the NR2E group, a subgroup of phylogenetically related members of the nuclear receptor (NR) superfamily of transcription factors. We assessed the ability of these NRs to form heterodimers with other members of the human NRs representing all major subgroups. The TLX ligand-binding domain (LBD) did not appear to form homodimers or interact directly with any other NR tested. The PNR LBD was able to form homodimers, but also exhibited robust interactions with the LBDs of peroxisome proliferator-activated receptor-γ (PPARγ)/NR1C3 and thyroid hormone receptor b (TRb) TRβ/NR1A2. The binding of PNR to PPARγ was specific for this paralog, as no interaction was observed with the LBDs of PPARα/NR1C1 or PPARδ/NR1C2. In support of these findings, PPARγ and PNR were found to be co-expressed in human retinal tissue extracts and could be co-immunoprecipitated as a native complex. Selected sequence variants in the PNR LBD associated with human retinopathies, or a mutation in the dimerization region of PPARγ LBD associated with familial partial lipodystrophy type 3, were found to disrupt PNR/PPARγ complex formation. Wild-type PNR, but not a PNR309G mutant, was able to repress PPARγ-mediated transcription in reporter assays. In summary, our results reveal novel heterodimer interactions in the NR superfamily, suggesting previously unknown functional interactions of PNR with PPARγ and TRβ that have potential importance in retinal development and disease.
- 16 March 2017
- Published by Springer Nature in Cell Death & Disease
- Vol. 8 (3) , e2677
Open AccessHeterodimers of photoreceptor-specific nuclear receptor (PNR/NR2E3) and peroxisome proliferator-activated receptor-γ (PPARγ) are disrupted by retinal disease-associated mutations
Photoreceptor-specific nuclear receptor (PNR/NR2E3) and Tailless homolog (TLX/NR2E1) are human orthologs of the NR2E group, a subgroup of phylogenetically related members of the nuclear receptor (NR) superfamily of transcription factors. We assessed the ability of these NRs to form heterodimers with other members of the human NRs representing all major subgroups. The TLX ligand-binding domain (LBD) did not appear to form homodimers or interact directly with any other NR tested. The PNR LBD was able to form homodimers, but also exhibited robust interactions with the LBDs of peroxisome proliferator-activated receptor-γ (PPARγ)/NR1C3 and thyroid hormone receptor b (TRb) TRβ/NR1A2. The binding of PNR to PPARγ was specific for this paralog, as no interaction was observed with the LBDs of PPARα/NR1C1 or PPARδ/NR1C2. In support of these findings, PPARγ and PNR were found to be co-expressed in human retinal tissue extracts and could be co-immunoprecipitated as a native complex. Selected sequence variants in the PNR LBD associated with human retinopathies, or a mutation in the dimerization region of PPARγ LBD associated with familial partial lipodystrophy type 3, were found to disrupt PNR/PPARγ complex formation. Wild-type PNR, but not a PNR309G mutant, was able to repress PPARγ-mediated transcription in reporter assays. In summary, our results reveal novel heterodimer interactions in the NR superfamily, suggesting previously unknown functional interactions of PNR with PPARγ and TRβ that have potential importance in retinal development and disease.
- 21 September 2016
- Published by Bioscientifica in Endocrine Abstracts
Lysine demethylase 7A (KDM7A) as a potential therapeutic target in prostate cancer
Androgen Receptor (AR) is central to prostate cancer (PCa) tumorigenesis and metastases. The genomic actions of androgens are mediated by the AR in complex with multiple chromatin modifying coregulators. We and others have identified lysine demethylases (KDMs) as important mediators of androgen signaling and increased expression of specific coregulators, including KDM1A, are implicated in PCa recurrence. There is an urgent need for new PCa treatments. While androgen deprivation therapies (ADT) impede tumor progression, castrate resistant PCa (CRPC) typically arises within ~18 months. CRPCs escape androgen dependency and are incurable. The mechanisms involved in CRPC include AR mutations/splice variants and/or alterations in AR-coregulators. However AR-coregulators, in particular ‘druggable’ enzymes including KDMs, offer alternative targets to circumvent resistance to existing ADTs. We reported that the androgen-induced microRNA-137 (miR137) acts as a suppressor of an extended network of transcriptional coregulators, including KDM1A and KDM7A, in normal prostate cells. However loss of miR137 in PCa contributes to increased expression of these coregulators. Here we report that androgen induces KDM7A expression in hormone responsive LNCaP cells. siRNA-mediated functional depletion of KDM7A expression impairs androgen induction of KLK3/PSA and the pro-angiogenesis factor VEGFA in LNCaP and its hormone-refractory derivative, LNCaP:C4-2. We examined KDM7A expression in PCa specimens and correlate expression with key clinical parameters. Collectively our data supports a role for KDM7A in androgen dependent and refractory PCa. Thus KDM7A, like KDM1A, represents a novel potential drug-target to inhibit androgen signaling in hormone dependent and refractory contexts and thereby potentially circumvent resistance to existing ADTs. Funding: We gratefully acknowledge the financial support of the BBSRC doctoral training program and the University of Nottingham. Presenting author: Veronika Metzler, Faculty of Medicine and Health Sciences, School of Veterinary Medicine and Health Sciences, University of Nottingham, UK. Email: stxvm8@nottingham.ac.uk.
- 21 September 2016
- Published by Bioscientifica in Endocrine Abstracts
Lysine demethylase 7A (KDM7A) as a potential therapeutic target in prostate cancer
Androgen Receptor (AR) is central to prostate cancer (PCa) tumorigenesis and metastases. The genomic actions of androgens are mediated by the AR in complex with multiple chromatin modifying coregulators. We and others have identified lysine demethylases (KDMs) as important mediators of androgen signaling and increased expression of specific coregulators, including KDM1A, are implicated in PCa recurrence. There is an urgent need for new PCa treatments. While androgen deprivation therapies (ADT) impede tumor progression, castrate resistant PCa (CRPC) typically arises within ~18 months. CRPCs escape androgen dependency and are incurable. The mechanisms involved in CRPC include AR mutations/splice variants and/or alterations in AR-coregulators. However AR-coregulators, in particular ‘druggable’ enzymes including KDMs, offer alternative targets to circumvent resistance to existing ADTs. We reported that the androgen-induced microRNA-137 (miR137) acts as a suppressor of an extended network of transcriptional coregulators, including KDM1A and KDM7A, in normal prostate cells. However loss of miR137 in PCa contributes to increased expression of these coregulators. Here we report that androgen induces KDM7A expression in hormone responsive LNCaP cells. siRNA-mediated functional depletion of KDM7A expression impairs androgen induction of KLK3/PSA and the pro-angiogenesis factor VEGFA in LNCaP and its hormone-refractory derivative, LNCaP:C4-2. We examined KDM7A expression in PCa specimens and correlate expression with key clinical parameters. Collectively our data supports a role for KDM7A in androgen dependent and refractory PCa. Thus KDM7A, like KDM1A, represents a novel potential drug-target to inhibit androgen signaling in hormone dependent and refractory contexts and thereby potentially circumvent resistance to existing ADTs. Funding: We gratefully acknowledge the financial support of the BBSRC doctoral training program and the University of Nottingham. Presenting author: Veronika Metzler, Faculty of Medicine and Health Sciences, School of Veterinary Medicine and Health Sciences, University of Nottingham, UK. Email: stxvm8@nottingham.ac.uk.
- Open Access
- 5 October 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (34) , 35710-35725
MiR137is an androgen regulated repressor of an extended network of transcriptional coregulators
MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators
- 5 October 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (34) , 35710-35725
Open AccessMiR137is an androgen regulated repressor of an extended network of transcriptional coregulators
MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators